Nebivolol effects on myocardial remodelling, inflammation markers and endothelial dysfunction in chronic heart failure patients with or without Type 2 diabetes mellitus
In patients with chronic heart failure (CHF), persistent neuro-humoral activation of sympatho-adrenal system and hyperglycaemia facilitate the activation of pro-cytokine inflammation component, as one of the pathophysiological mechanisms of endothelial dysfunction (ED). Aim. To study nebivolol effec...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2011-02-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1466 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850028087909023744 |
|---|---|
| author | Yu. N. Belenkov E. V. Privalova I. S. Chekneva L. V. Knyazeva N. S. Suleymanova I. V. Vasilyeva |
| author_facet | Yu. N. Belenkov E. V. Privalova I. S. Chekneva L. V. Knyazeva N. S. Suleymanova I. V. Vasilyeva |
| author_sort | Yu. N. Belenkov |
| collection | DOAJ |
| description | In patients with chronic heart failure (CHF), persistent neuro-humoral activation of sympatho-adrenal system and hyperglycaemia facilitate the activation of pro-cytokine inflammation component, as one of the pathophysiological mechanisms of endothelial dysfunction (ED). Aim. To study nebivolol effects on clinical and functional status, left ventricular (LV) myocardial remodelling, inflammation markers, and ED in CHF patients with or without Type 2 diabetes mellitus (DM-2).Material and methods. The study included 65 patients with functional class (FC) I-III CHF (NYHA classification) of ischemic origin and LV ejection fraction (EF) <50%. Mean age was 61,2±7,4 years; 35 participants were diagnosed with DM-2. Results. Additional beneficial effects of nebivolol, such as endogenous NO synthesis modulation and immune inflammation reduction, could explain its clinical effectiveness and prognosis improvement in patients with CHF and DM-2, as well as in CHF patients with normal carbohydrate metabolism.Conclusion. Hyperglycaemia has an important negative effect on anti-inflammatory defence mechanisms, CHF clinical course, and prognosis, which was demonstrated by high baseline levels of all clinical and hemodynamic parameters, inflammation markers, and ED in patients with CHF and DM-2. |
| format | Article |
| id | doaj-art-7579131ac37349ab88a1dc7d6b31a565 |
| institution | DOAJ |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2011-02-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-7579131ac37349ab88a1dc7d6b31a5652025-08-20T02:59:56Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252011-02-0110166721180Nebivolol effects on myocardial remodelling, inflammation markers and endothelial dysfunction in chronic heart failure patients with or without Type 2 diabetes mellitusYu. N. Belenkov0E. V. Privalova1I. S. Chekneva2L. V. Knyazeva3N. S. Suleymanova4I. V. Vasilyeva5I.M. Sechenov First Moscow State Medical InstituteI.M. Sechenov First Moscow State Medical InstituteI.M. Sechenov First Moscow State Medical InstituteI.M. Sechenov First Moscow State Medical InstituteI.M. Sechenov First Moscow State Medical InstituteI.M. Sechenov First Moscow State Medical InstituteIn patients with chronic heart failure (CHF), persistent neuro-humoral activation of sympatho-adrenal system and hyperglycaemia facilitate the activation of pro-cytokine inflammation component, as one of the pathophysiological mechanisms of endothelial dysfunction (ED). Aim. To study nebivolol effects on clinical and functional status, left ventricular (LV) myocardial remodelling, inflammation markers, and ED in CHF patients with or without Type 2 diabetes mellitus (DM-2).Material and methods. The study included 65 patients with functional class (FC) I-III CHF (NYHA classification) of ischemic origin and LV ejection fraction (EF) <50%. Mean age was 61,2±7,4 years; 35 participants were diagnosed with DM-2. Results. Additional beneficial effects of nebivolol, such as endogenous NO synthesis modulation and immune inflammation reduction, could explain its clinical effectiveness and prognosis improvement in patients with CHF and DM-2, as well as in CHF patients with normal carbohydrate metabolism.Conclusion. Hyperglycaemia has an important negative effect on anti-inflammatory defence mechanisms, CHF clinical course, and prognosis, which was demonstrated by high baseline levels of all clinical and hemodynamic parameters, inflammation markers, and ED in patients with CHF and DM-2.https://cardiovascular.elpub.ru/jour/article/view/1466chronic heart failuretype 2 diabetes mellitusnebivololpro-inflammatory cytokinesendothelial dysfunctionbiomarkers |
| spellingShingle | Yu. N. Belenkov E. V. Privalova I. S. Chekneva L. V. Knyazeva N. S. Suleymanova I. V. Vasilyeva Nebivolol effects on myocardial remodelling, inflammation markers and endothelial dysfunction in chronic heart failure patients with or without Type 2 diabetes mellitus Кардиоваскулярная терапия и профилактика chronic heart failure type 2 diabetes mellitus nebivolol pro-inflammatory cytokines endothelial dysfunction biomarkers |
| title | Nebivolol effects on myocardial remodelling, inflammation markers and endothelial dysfunction in chronic heart failure patients with or without Type 2 diabetes mellitus |
| title_full | Nebivolol effects on myocardial remodelling, inflammation markers and endothelial dysfunction in chronic heart failure patients with or without Type 2 diabetes mellitus |
| title_fullStr | Nebivolol effects on myocardial remodelling, inflammation markers and endothelial dysfunction in chronic heart failure patients with or without Type 2 diabetes mellitus |
| title_full_unstemmed | Nebivolol effects on myocardial remodelling, inflammation markers and endothelial dysfunction in chronic heart failure patients with or without Type 2 diabetes mellitus |
| title_short | Nebivolol effects on myocardial remodelling, inflammation markers and endothelial dysfunction in chronic heart failure patients with or without Type 2 diabetes mellitus |
| title_sort | nebivolol effects on myocardial remodelling inflammation markers and endothelial dysfunction in chronic heart failure patients with or without type 2 diabetes mellitus |
| topic | chronic heart failure type 2 diabetes mellitus nebivolol pro-inflammatory cytokines endothelial dysfunction biomarkers |
| url | https://cardiovascular.elpub.ru/jour/article/view/1466 |
| work_keys_str_mv | AT yunbelenkov nebivololeffectsonmyocardialremodellinginflammationmarkersandendothelialdysfunctioninchronicheartfailurepatientswithorwithouttype2diabetesmellitus AT evprivalova nebivololeffectsonmyocardialremodellinginflammationmarkersandendothelialdysfunctioninchronicheartfailurepatientswithorwithouttype2diabetesmellitus AT ischekneva nebivololeffectsonmyocardialremodellinginflammationmarkersandendothelialdysfunctioninchronicheartfailurepatientswithorwithouttype2diabetesmellitus AT lvknyazeva nebivololeffectsonmyocardialremodellinginflammationmarkersandendothelialdysfunctioninchronicheartfailurepatientswithorwithouttype2diabetesmellitus AT nssuleymanova nebivololeffectsonmyocardialremodellinginflammationmarkersandendothelialdysfunctioninchronicheartfailurepatientswithorwithouttype2diabetesmellitus AT ivvasilyeva nebivololeffectsonmyocardialremodellinginflammationmarkersandendothelialdysfunctioninchronicheartfailurepatientswithorwithouttype2diabetesmellitus |